06-11-2017, 11:42 PM
In fact, Cramer found that the CANDIES stocks — Chipotle, Apple, Netflix, Deckers, Intuitive Surgical, Express Scripts, and Salesforce.com — are up 281 percent on average since he formed the acronym in 2010, versus 121 percent for the S&P 500 index. The "Mad Money" host picked these particular names because they were some of the best growth stocks of the time, and oddly, they remain some of the strongest performers today.
Cramer revisits a pre-FANG acronym to see if those stocks kept growing
Can any strategy consistently beat the market? Increasingly, it doesn’t look like it. According to UBS, one of the hottest investment trends on Wall Street—one that has been touted as a way to zero in on securities with desirable characteristics for relatively cheap fees—has struggled to outperform over long periods of time. So-called “smart beta” funds, which use rules to develop portfolios with certain strategic tilts, like “value,” “low volatility,” or “momentum,” have in large part done worse than the overall market, particularly when fees are taken into account. Tally another point in the pro-indexing column, its proponents.
The track record for ‘smart beta’ ETFs provides more fuel for indexing camp - MarketWatch
The Digital Hub Initiative is the German government’s big move to strengthen connectivity and cooperation between startups in a digital age. In general, Germany has always done well in startup reports, with cities like Berlin usually getting high scores. But the international competition is fierce and there’s always room for improvement.
Europe's biggest economy uniting tech hubs to dethrone Silicon Valley - Business Insider
Older people who received transfusions of young blood plasma have shown improvements in biomarkers related to cancer, Alzheimer’s disease and heart disease, New Scientist has learned. “I don’t want to say the word panacea, but here’s something about teenagers,” Jesse Karmazin, founder of startup Ambrosia, told New Scientist. “Whatever is in young blood is causing changes that appear to make the ageing process reverse.” Since August 2016, Karmazin’s company has been transfusing people aged 35 and older with plasma – the liquid component of blood – taken from people aged between 16 and 25. So far, 70 people have been treated, all of whom paid Ambrosia to be included in the study.
Human tests suggest young blood cuts cancer and Alzheimer's risk | New Scientist
Harvard medicine professor Ted Kaptchuk is at the bleeding edge of a radical new treatment in medicine: giving patients pills that don’t work. “Our patients tell us it’s nuts,” he says. “The doctors think it’s nuts. And we just do it. And we’ve been getting good results.” In medicine, placebo pills are typically used as a tool to test the effectiveness of real drugs. In a double-blind, placebo-controlled clinical trial, which researchers consider the gold standard for testing a drug’s effects, patients (and the doctors running the trial) don’t know who’s taking the real drug and who’s taking the placebo.
A radical new hypothesis in medicine: give patients drugs they know don’t work - Vox